Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

SEMA4C as a Relapse Biomarker in Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03663153
Recruitment Status : Not yet recruiting
First Posted : September 10, 2018
Last Update Posted : September 10, 2018
Hubei Cancer Hospital
Qilu Hospital of Shandong University
Wuhan central hospital
Xiangyang Central Hospital
The First People's Hospital of Jingzhou
The First Affiliated Hospital with Nanjing Medical University
Information provided by (Responsible Party):
Qinglei Gao, Tongji Hospital